================================================================================
CLINICAL TRIALS MATCHING REPORT
================================================================================

Patient ID: 1
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
01/2017 V.a. neue Lebermetastase
02/2017 Start Somatoline
02/2018 CT Abdomen: stable disease
03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. 
Clinical Question: Weitere Therapie?
Report generated: 2025-07-10 10:49:42

Found 15 relevant clinical trials
--------------------------------------------------------------------------------

1. 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
   NCT ID: NCT06395402
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.850
   Relevance Reason: Die Studie ist für diesen Patienten sehr relevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was exakt der Indikation für die Behandlung mit Lutetium-177 DOTATATE (Lutathera) entspricht, die in der Studie untersucht wird. Die Studie evaluiert eine modifizierte Dosierung von Lutathera basierend auf individueller Dosimetrie, was potenziell zu einer effektiveren und sichereren Behandlung führen könnte.
   Condition: Neuroendocrine Tumors; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2
   Intervention: Lutetium Lu 177 dotatate therapy
   Sponsor: University of Iowa
   Start Date: 2024-05-03
   Completion Date: 2029-12-31
   Locations: Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, United States
   URL: https://clinicaltrials.gov/study/NCT06395402
   Summary: The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will:

* Undergo Somatostatin Recept...
----------------------------------------

2. Open-Label Surufatinib in European Patients With NET
   NCT ID: NCT04579679
   Status: COMPLETED
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie scheint für den Patienten sehr relevant zu sein. Der Patient hat ein neuroendokrines Tumor (NET) des Dünndarms mit Lebermetastasen. Die Studie untersucht Surufatinib bei Patienten mit niedrig- bis mittelgradigen (Grad 1 oder 2), gut differenzierten NETs. Der ursprüngliche Tumor des Patienten war ein G1 NET, was in den Einschlusskriterien der Studie liegt. Die Studie hat eine spezifische Kohorte (Kohorte B) für NETs des Dünndarms.
   Condition: Neuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NET
   Intervention: Surufatinib
   Sponsor: Hutchmed
   Start Date: 2021-08-13
   Completion Date: 2024-10-15
   Locations: University of Alabama, Birmingham (UAB), Birmingham, United States; University of California Irvine Medical Center UCIMC - H.H. Chao Comprehensive Digestive Disease Center CDDC, Orange, United States; Emory University, Winship Cancer Institute, Atlanta, United States
   URL: https://clinicaltrials.gov/study/NCT04579679
   Summary: This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
----------------------------------------

3. Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
   NCT ID: NCT04917484
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie "Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients" ist für diesen Patienten hochrelevant.
   Condition: Neuroendocrine Neoplasm
   Intervention: Lu-177-DOTA-Octreotide
   Sponsor: Tine Gregersen, MD
   Start Date: 2020-02-01
   Completion Date: 2026-12
   Locations: Aarhus University Hospital, department of Nuclear medicine and PET centre, Aarhus, Denmark
   URL: https://clinicaltrials.gov/study/NCT04917484
   Summary: In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTAT...
----------------------------------------

4. Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
   NCT ID: NCT03420521
   Status: TERMINATED
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie scheint für den Patienten sehr relevant zu sein. Der Patient leidet an einem gut differenzierten neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was direkt der Studienindikation entspricht ("advanced or metastatic thoracic, GI or pancreatic well-differentiated neuroendocrine tumors"). Die Progression der Lebermetastasen (V.a. gering progrediente Lebermetastasen 03/2019) deutet darauf hin, dass der Patient eine Therapie benötigt, und die Studie untersucht eine neue Therapieoption (Nivolumab und Ipilimumab) für Patienten, bei denen die Standardtherapie (Somatoline in diesem Fall) möglicherweise nicht ausreichend wirksam ist.
   Condition: Neuroendocrine Tumors; Carcinoid Tumor
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
   Start Date: 2018-03-09
   Completion Date: 2021-11-24
   Locations: Johns Hopkins Medical Institution, Baltimore, United States
   URL: https://clinicaltrials.gov/study/NCT03420521
   Summary: This is a single arm open-label design study looking at Nivolumab plus Ipilimumab in patients with Advanced Neuroendocrine Tumors. Patients will be dosed Nivolumab 240mg IV over 60 minutes every 2 weeks (Q2W) and Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W). One cycle will include 3 dose...
----------------------------------------

5. Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT03043664
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors" ist für diesen Patienten hochrelevant.
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: Lanreotide; Pembrolizumab
   Sponsor: Duke University
   Start Date: 2017-07-01
   Completion Date: 2022-06-07
   Locations: Duke University Medical Center, Durham, United States; Lexington Medical Center, Columbia, United States
   URL: https://clinicaltrials.gov/study/NCT03043664
   Summary: This study is for patients with non-resectable, recurrent, or metastatic well or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The study will be conducted in two stages: 1) Safety Run-In and 2) Expanded Cohort.

1. Safety run-in: The first stage will include a s...
----------------------------------------

6. Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
   NCT ID: NCT06878664
   Status: RECRUITING
   Phase: PHASE3
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant. Der Patient leidet an einem NET des Dünndarms mit Lebermetastasen, was direkt der Zielpopulation der Studie entspricht ("advanced midgut neuroendocrine tumors"). Die Studie untersucht die Optimierung der Lutetium-Dotatate-Therapie (RLT), welche bereits beim Patienten in Betracht gezogen wird (Somatoline ist ein Somatostatin-Analogon, das oft vor oder begleitend zur RLT eingesetzt wird).
   Condition: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
   Intervention: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Amino acid solution; Lanreotide (Autogel formulation) or Octreotide LAR
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2025-07
   Completion Date: 2029-01
   Locations: Hopital BEAUJON, Clichy, France; Centre François BACLESSE, Caen, France; Chu Dijon, Dijon, France
   URL: https://clinicaltrials.gov/study/NCT06878664
   Summary: This is a randomized Phase II/late phase I de-escalation clinical trial with approved investigational medicinal products in new use condition, low intervention.

Disease under study Patients with unresectable or metastatic, slowly progressive, well-differentiated (Grade1 and Grade2), somatostatin re...
----------------------------------------

7. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
   NCT ID: NCT05724108
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was exakt der Indikation der Studie entspricht ("Metastatic Neuroendocrine Tumors"). Der Patient wurde bereits mit Somatoline behandelt, was auf eine fortgeschrittene Erkrankung hindeutet, bei der neue Therapieoptionen in Betracht gezogen werden müssen. Die Studie untersucht die Kombination von Triapine mit Lutetium Lu 177 Dotatate, einer etablierten Therapie für NETs, mit dem Ziel, die Ansprechrate und das progressionsfreie Überleben zu verbessern.
   Condition: Metastatic Neuroendocrine Tumor
   Intervention: Biospecimen Collection; Computed Tomography; Lutetium Lu 177 Dotatate; Magnetic Resonance Imaging; Triapine
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2023-08-30
   Completion Date: 2025-09-30
   Locations: City of Hope Comprehensive Cancer Center, Duarte, United States; UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, United States; UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, United States
   URL: https://clinicaltrials.gov/study/NCT05724108
   Summary: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other pl...
----------------------------------------

8. Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
   NCT ID: NCT05359146
   Status: RECRUITING
   Phase: EARLY_PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für den Patienten sehr relevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was direkt der in der Studie genannten Erkrankungsgruppe (Neuroendocrine Neoplasia's - NENs) entspricht. Die Studie fokussiert sich auf die Verbesserung der PRRT, einer etablierten Therapieoption für NETs, und der Patient hat bereits Somatoline (ein Somatostatin-Analogon) erhalten, was auf eine mögliche Eignung für PRRT hindeutet.
   Condition: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
   Intervention: 161Tb-DOTA-LM3; 177Lu-DOTATOC
   Sponsor: University Hospital, Basel, Switzerland
   Start Date: 2023-03-28
   Completion Date: 2025-12
   Locations: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
   URL: https://clinicaltrials.gov/study/NCT05359146
   Summary: The goal of this phase 0 proof-of concept study is to measure the therapeutic index (tumour to dose-limiting-organ dose ratios) of 161Tb-DOTA-LM3 in comparison to the current standard 177Lu-DOTATOC in the same gastroenteropancreatic neuroendocrine tumour (GEP-NET) patients in a randomized, cross-ove...
----------------------------------------

9. Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
   NCT ID: NCT05987176
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten sehr relevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was exakt der Indikation der Studie entspricht ("Neuroendocrine Liver Metastases"). Die Studie vergleicht eine adjuvante Therapie mit 177Lu-DOTATATE nach Resektion der Lebermetastasen mit der besten unterstützenden Behandlung.
   Condition: Neuroendocrine Tumor G1 (NET G1)/Carcinoid; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumors; Liver Metastases; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Neoplasm
   Intervention: Lutathera
   Sponsor: Imperial College London
   Start Date: 2024-08-02
   Completion Date: 2029-03-30
   Locations: Imperial College Healthcare NHS Trust, London, United Kingdom
   URL: https://clinicaltrials.gov/study/NCT05987176
   Summary: An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver metastases.

In this study, adjuvant treatment with 177Lu-DOTATATE will be compa...
----------------------------------------

10. 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
   NCT ID: NCT05673031
   Status: RECRUITING
   Phase: N/A
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten hochrelevant. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was direkt der Zielgruppe der Studie entspricht. Die Studie untersucht die Nützlichkeit von 68Ga-HA-DOTATATE PET/CT bei NETs, sowohl in der Primärdiagnostik als auch in der Surveillance nach Resektion.
   Condition: Neuroendocrine Tumors (NET)
   Intervention: 68Ga-HA-DOTATATE PET/CT imaging
   Sponsor: Alberta Health services
   Start Date: 2023-02-01
   Completion Date: 2027-01-01
   Locations: Foothills Medical Center 1403 29 St NW, Calgary, Canada
   URL: https://clinicaltrials.gov/study/NCT05673031
   Summary: To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]
----------------------------------------

11. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Relevance Score: 0.800
   Relevance Reason: Die Studie ist für diesen Patienten sehr relevant. Der Patient hat ein Dünndarm-NET mit Lebermetastasen und Lymphknotenbefall, was direkt in die Studienindikation von GEP-NETs fällt. Die Studie untersucht die Verwendung einer Beta-Sonde in Kombination mit 68Ga-DOTATOC PET/CT, um Tumore und Metastasen präziser zu lokalisieren, insbesondere in Lymphknoten, was bei diesem Patienten von Bedeutung ist, da Lymphknotenmetastasen bereits bekannt sind und die Prognose beeinflussen.
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
----------------------------------------

12. A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
   NCT ID: NCT01262235
   Status: COMPLETED
   Phase: PHASE1
   Relevance Score: 0.800
   Relevance Reason: Die Studie "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients" ist für diesen Patienten hochrelevant.
   Condition: Cancer; Neuroendocrine Tumors; NET; Adrenocortical Carcinoma; ACC
   Intervention: TKM-080301
   Sponsor: Arbutus Biopharma Corporation
   Start Date: 2010-12
   Completion Date: 2015-08
   Locations: Scottsdale Healthcare Research Institute, Scottsdale, United States; Mayo Clinic Arizona, Scottsdale, United States; Moffitt Cancer Center, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT01262235
   Summary: This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for who...
----------------------------------------

13. Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
   NCT ID: NCT06784752
   Status: RECRUITING
   Phase: PHASE3
   Relevance Score: 0.800
   Relevance Reason: Die Studie scheint für diesen Patienten sehr relevant zu sein. Hier ist eine detaillierte Begründung:
   Condition: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
   Intervention: [177Lu]Lu-DOTA-TATE; Octreotide LAR
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2025-05-30
   Completion Date: 2034-01-05
   Locations: Highlands Oncology Group, Fayetteville, United States; Rocky Mountain Cancer Centers, Denver, United States; Piedmont Hematology And Oncology, Winston-Salem, United States
   URL: https://clinicaltrials.gov/study/NCT06784752
   Summary: The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<...
----------------------------------------

14. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
   NCT ID: NCT01174121
   Status: RECRUITING
   Phase: PHASE2
   Relevance Score: 0.750
   Relevance Reason: Die Studie ist für den Patienten durchaus relevant. Der Patient leidet an einem metastasierten neuroendokrinen Tumor (NET) des Dünndarms, was explizit in den Einschlusskriterien der Studie genannt wird ("endocrine tumors including neuroendocrine tumors refractory to standard chemotherapy"). Der Patient hat bereits eine Erstlinienbehandlung mit Somatoline erhalten und zeigt Anzeichen einer Progression, was ihn für eine Studie geeignet macht, die Therapien für refraktäre Erkrankungen untersucht.
   Condition: Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors
   Intervention: Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-08-26
   Completion Date: 2029-12-27
   Locations: National Institutes of Health Clinical Center, Bethesda, United States
   URL: https://clinicaltrials.gov/study/NCT01174121
   Summary: Background:

The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we...
----------------------------------------

15. Open-label Study of Surufatinib in Japanese Patients
   NCT ID: NCT05077384
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE1
   Relevance Score: 0.700
   Relevance Reason: Die Studie scheint für den Patienten relevant zu sein, wenn auch nicht perfekt passend. Der Patient leidet an einem neuroendokrinen Tumor (NET) des Dünndarms mit Lebermetastasen, was direkt mit dem Fokus von Teil 2 der Studie übereinstimmt ("evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs").
   Condition: Neuroendocrine Tumors; Non-hematologic Malignancy
   Intervention: Surufatinib
   Sponsor: Hutchmed
   Start Date: 2021-09-02
   Completion Date: 2024-12
   Locations: Kyushu University Hospital, Fukuoka, Japan; Fukuoka Sanno Hospital, Fukuoka, Japan; Kagawa University Hospital, Kagawa, Japan
   URL: https://clinicaltrials.gov/study/NCT05077384
   Summary: This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.
----------------------------------------